Steven Jon Russell Sells 4,222 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Steven Jon Russell sold 4,222 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total value of $53,239.42. Following the transaction, the insider directly owned 173,849 shares of the company’s stock, valued at $2,192,235.89. This represents a 2.37% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Stock Performance

NASDAQ BBNX opened at $13.89 on Friday. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The stock has a market capitalization of $618.94 million, a PE ratio of -9.20 and a beta of 3.40. The stock has a 50-day simple moving average of $10.88 and a 200 day simple moving average of $17.21.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.04. The business had revenue of $27.63 million during the quarter. Beta Bionics had a negative return on equity of 23.00% and a negative net margin of 60.27%. As a group, equities research analysts forecast that Beta Bionics, Inc. will post -2.19 EPS for the current fiscal year.

Institutional Investors Weigh In On Beta Bionics

Large investors have recently modified their holdings of the stock. Summit Securities Group LLC bought a new stake in shares of Beta Bionics in the 4th quarter valued at approximately $52,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after purchasing an additional 1,818 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the period. Strs Ohio bought a new stake in shares of Beta Bionics in the 1st quarter valued at approximately $29,000. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Beta Bionics by 139.1% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after purchasing an additional 1,863 shares during the period.

Analyst Ratings Changes

BBNX has been the subject of several recent research reports. Lake Street Capital set a $20.00 price target on Beta Bionics in a report on Wednesday, February 18th. Leerink Partners cut their price target on Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a report on Sunday, March 29th. Weiss Ratings cut Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Finally, The Goldman Sachs Group cut their price target on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $19.70.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics recently said it is publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support transparency and commercial momentum. Article Title
• Neutral Sentiment: Several insider stock sales were disclosed, but the company said they were made to cover tax obligations related to equity award vesting, making the impact less concerning than discretionary selling.
• Negative Sentiment: Johnson Fistel and Robbins LLP announced investigations into Beta Bionics and its officers over possible securities-law violations tied to investor losses and slower new patient start growth, creating a legal overhang. Article Title

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.